ABBV
ABBVIE INC.
stockNYSE
At CloseOct 6, 2026 3:59:57 PM EDT
266.76USD+0.376%(+1.00)4,411,548
259.00Bid266.88Ask7.88SpreadPre-marketOct 6, 2026 9:28:30 AM EDT
267.35USD+0.598%(+1.59)
After-hoursOct 6, 2026 4:10:30 PM EDT
266.69USD-0.026%(-0.07)
Loading…
Loading…
471.17B
Healthcare
Drug Manufacturers-General
CEO
Richard Gonzalez
HQ
North Chicago, IL, USA
30,000
Previous Close
$265.76
Beta
-0.11
52-Week High
$269.39 2026-09-23
52-Week Low
$190.75 2026-04-29
SMA 50
$257.97
SMA 200
$231.73
Avg. Vol 10D
4.24M
Avg. Vol 30D
4.24M
Avg. Vol 90D
5.92M
Relative Vol
0.64
1.77B
1.76B
99.80%
19,494,556
1.11%
4.48
54%/46%
55.14%
26.77%
0.4100%
6,000,000
16,029
6,774
16,029
Oct 30, 2026 (24d)
Apr 15, 2025 · $1.640
Oct 6, 2026
3 of the Best Growth Stocks to Buy in October 2026 · 
The Motley Fool
3 of the Best Growth Stocks to Buy in October 2026 · The Motley Fool
ABBV Profile
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
ABBV Performance
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 263.29 | 2026-09-29 | +1.27% | 2.129 |
| 1M | 248.78 | 2026-09-08 | +7.17% | 0.008 |
| 3M | 254.76 | 2026-07-06 | +4.66% | -0.424 |
| 6M | 206.69 | 2026-04-06 | +29.00% | -0.390 |
| 1Y | 230.19 | 2025-10-06 | +15.83% | -0.110 |
| 2Y | 193.61 | 2024-10-07 | +37.72% | — |
| 5Y | 109.32 | 2021-10-06 | +143.90% | 0.289 |
ABBV Stock Summary
ABBVIE INC. (NYSE:ABBV) stock price today is $266.63, and today's volume is 2,695,023. ABBV is up 0.327% today. The 30 day average volume is 4.24M. ABBV market cap is $471.17B with 1.77B shares outstanding.